Examples of using Clinically relevant differences in English and their translations into Greek
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Official/political
-
Computer
No clinically relevant differences were noted between the two populations.
A population PK analysis did not identify clinically relevant differences in PK of cabozantinib based on race.
No clinically relevant differences in pharmacokinetics according to age or ethnicity have been identified.
In a study in healthy Japanese andCaucasian subjects no clinically relevant differences in pharmacokinetic parameters were observed.
There are no clinically relevant differences in pharmacokinetics between Caucasian and Asian subjects.
Based on pharmacokinetic data from studies in Japanese and Chinese patients with prostate cancer,there were no clinically relevant differences in exposure among the populations.
There were no clinically relevant differences in Cmax compared to healthy volunteers.
The analysis of the impact of NSCLC histology on overall survival demonstrated clinically relevant differences in survival according to histology, see table below.
No clinically relevant differences in pharmacokinetics of rilpivirine have been observed between men and women.
In a population pharmacokinetic analysis of eravacycline, no clinically relevant differences in the pharmacokinetics of eravacycline were observed with respect to age.
No clinically relevant differences in tenofovir pharmacokinetics were observed between subjects with hepatic impairment and healthy subjects.
This can lead to graft rejection or increased incidence of adverse reactions, including under- oroverimmunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus.
There were no clinically relevant differences observed in saxagliptin pharmacokinetics between males and females.
Pharmacokinetic studies in Thai, Chinese andJapanese healthy subjects did not identify any clinically relevant differences in the pharmacokinetics of zanamivir in these populations compared with Caucasians.
There were no clinically relevant differences in safety between males(N=382) and females(N=139) in the FLAGS study.
No clinically relevant differences in cobicistat pharmacokinetics were observed between subjects with moderate impairment and healthy subjects.
The results demonstrated no clinically relevant differences between sildenafil and placebo in time to limiting angina.
No clinically relevant differences in tenofovir alafenamide or tenofovir pharmacokinetics were observed between adolescent and adult HIV-1 infected subjects.
Elderly: There are no clinically relevant differences due to age in the pharmacokinetics of cinacalcet.
There were no clinically relevant differences in empagliflozin pharmacokinetics between healthy volunteers and patients with type 2 diabetes.
There were no clinically relevant differences in systemic exposures between White, Black or Asian races.
There were no clinically relevant differences observed for the safety profile of pemetrexed within the histology subgroups.
There were no clinically relevant differences observed for the safety profile of pemetrexed within the histology subgroups.
There are no clinically relevant differences in the rate of absorption when lixisenatide is administered subcutaneously in the abdomen, thigh, or arm.
No clinically relevant differences in elvitegravir or cobicistat pharmacokinetics were observed between subjects with severe renal impairment and healthy subjects.
There were no clinically relevant differences between genders in the pharmacokinetics of lurasidone in a population pharmacokinetic analysis in patients with schizophrenia.
There are no clinically relevant differences in the rate of absorption when lixisenatide as monotherapy is administered subcutaneously in the abdomen, deltoid, or thigh.
No clinically relevant differences were seen in the pharmacokinetics of repaglinide, when repaglinide was administered 0, 15 or 30 minutes before a meal or in fasting state.
No clinically relevant differences in the pharmacokinetics of vildagliptin were observed between male and female healthy subjects within a wide range of age and body mass index(BMI).
There were no clinically relevant differences in the safety population of the elderly subjects who received oseltamivir or placebo compared with the adult population aged up to 65 years.